Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapy

• Published in: Journal of human genetics Vol. 51; no. 9; pp. 822 - 826
• Main Authors: Takane, Hiroshi, Miyata, Masanori, Burioka, Naoto, Shigemasa, Chiaki, Shimizu, Eiji, Otsubo, Kenji, Ieiri, Ichiro
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.09.2006
• Subjects: Adult; Aged; Aged, 80 and over; Alleles; Anticholesteremic Agents - pharmacology; Apolipoprotein E; Apolipoproteins E - genetics; Cholesterol; Cholesterol 7-alpha-Hydroxylase - genetics; Female; Genes; Genetic diversity; Genotypes; Genotyping; Heterozygotes; Humans; Hydroxylase; Hypercholesterolemia - blood; Hypercholesterolemia - drug therapy; Hypercholesterolemia - genetics; Lipid metabolism; Lipids; Lipids - blood; Liver-Specific Organic Anion Transporter 1; Low density lipoprotein; Male; Middle Aged; Organic Anion Transporters - genetics; Pharmacogenetics; Pravastatin; Pravastatin - pharmacology; Statins

Pravastatin is mainly taken up from the circulation into the liver via organic anion-transporting polypeptide 1B1 (SLCO1B1 gene product). We examined the contribution of genetic variants in the SLCO1B1 gene and other candidate genes to the variability of pravastatin efficacy in 33 hypercholesterolem...